Related Experiment Video
Updated: Jun 23, 2025
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
CD117 expression in canine ovarian tumours
Hannah E Mallon1, Gustavo A Ramírez2, Tamara Dolenšek3
1Department of Pathobiology and Population Sciences, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Hertfordshire AL9 7TA, UK.
Journal of Comparative Pathology
|June 15, 2024
Summary
Canine ovarian tumours frequently express the tyrosine kinase receptor CD117, a potential biomarker. Normal ovarian tissue does not express CD117, suggesting its role in canine ovarian cancer.
Area of Science:
- Veterinary Pathology
- Oncology
- Molecular Biology
Background:
- Canine ovarian cancer presents diagnostic and therapeutic challenges.
- Tumor heterogeneity complicates histological identification.
- Current treatments are limited to surgical excision.
Purpose of the Study:
- To investigate the neoexpression of the tyrosine kinase receptor CD117 in canine ovarian tumours.
- To determine if CD117 can serve as a diagnostic or prognostic biomarker.
- To explore CD117 as a potential therapeutic target in canine ovarian cancer.
Main Methods:
- Immunohistochemistry was used to detect CD117 expression in 29 canine ovarian tumour samples.
- Semi-quantitative scoring assessed CD117 labelling intensity and location (membranous, cytoplasmic).
- Histological morphology, cytokeratin 7, mitotic index, necrosis, and vascular invasion were evaluated.
Main Results:
- 81% of canine ovarian tumours exhibited CD117 neoexpression, while normal ovarian tissue did not.
- CD117 was detected in both ovarian carcinomas and granulosa cell tumours.
- No significant association was found between CD117 expression and clinicopathological factors.
Conclusions:
- CD117 is neoexpressed in a majority of canine ovarian tumours, distinguishing them from normal tissue.
- CD117 represents a promising biomarker for canine ovarian tumours.
- Further research is required to define the prognostic and therapeutic implications of CD117.
